Using regulatory data

In my recent post I expressed frustration with the direction of travel of rapid reviews and one thing I highlighted was the lack of work on using regulatory data.  This prompted two responses highlighting two separate papers: How to use FDA drug approval documents for evidence syntheses, BMJ 2018 Practical guidance for using multiple data sources in systematic reviews and meta‐analyses (with examples from the … Continue reading Using regulatory data

Where are we going with rapid reviews? #frustrating

A while back I wrote a piece Different approaches to rapidity which suggested there are two ways of doing a rapid review: Process – take the systematic review and take short cuts Outcome – what’s the optimal way of getting to the desired outcome I’m increasingly concerned that all the focus is on the former and not the latter. My concern is based on a variety … Continue reading Where are we going with rapid reviews? #frustrating